We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.78%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.01B
AUM Growth
+$119M
Cap. Flow
-$210M
Cap. Flow %
-2.99%
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$40.7M
2
LLY icon
Eli Lilly
LLY
+$35.4M
3
MRK icon
Merck
MRK
+$34M
4
HUM icon
Humana
HUM
+$29.6M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$57.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$51M
3
BSX icon
Boston Scientific
BSX
+$40.6M
4
HCA icon
HCA Healthcare
HCA
+$39.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Industrials 0.87%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDY icon
101
Dr. Reddy's Laboratories
RDY
$10.5B
$5.79M 0.08%
458,500
-59,000
-11% -$689K
NVRO
102
DELISTED
NEVRO CORP.
NVRO
$5.56M 0.08%
218,573
– –
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
$5.39M 0.08%
748,667
– –
OLK
104
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$4.49M 0.06%
239,624
– –
SGEN
105
DELISTED
Seagen Inc. Common Stock
SGEN
$4.23M 0.06%
22,000
-700
-3% -$139K
JNJ icon
106
Johnson & Johnson
JNJ
$609B
$3.51M 0.05%
21,225
-1,680
-7% -$271K
COR icon
107
Cencora
COR
$59.9B
$3.06M 0.04%
15,910
– –
GH icon
108
Guardant Health
GH
$20.7B
$2.94M 0.04%
82,197
– –
ALKS icon
109
Alkermes
ALKS
$8.79B
$2.56M 0.04%
81,700
+17,500
+27% +$530K
CVS icon
110
CVS Health
CVS
$137B
$2.44M 0.03%
35,314
+12,500
+55% +$889K
SGHT icon
111
Sight Sciences
SGHT
$274M
$2.37M 0.03%
286,284
– –
KRTX
112
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.19M 0.03%
10,100
+2,800
+38% +$600K
KRYS icon
113
Krystal Biotech
KRYS
$10.5B
$2.11M 0.03%
18,000
-300
-2% -$30.6K
AMWL icon
114
American Well
AMWL
$221M
$2M 0.03%
47,681
-25,428
-35% -$1.12M
KOS icon
115
Kosmos Energy
KOS
$1.33B
$1.91M 0.03%
318,300
– –
ONC
116
BeOne Medicines Ltd
ONC
$32.4B
$1.82M 0.03%
10,200
-48,035
-82% -$11.1M
LH icon
117
Labcorp
LH
$23.2B
$1.69M 0.02%
8,134
– –
BBIO icon
118
BridgeBio Pharma
BBIO
$15.9B
$1.67M 0.02%
96,900
+14,300
+17% +$215K
MCK icon
119
McKesson
MCK
$98.5B
$1.41M 0.02%
3,296
+557
+20% +$214K
DNLI icon
120
Denali Therapeutics
DNLI
$3.7B
$1.3M 0.02%
44,050
+13,050
+42% +$367K
PCVX icon
121
Vaxcyte
PCVX
$8.12B
$1.3M 0.02%
+26,000
New +$1.23M
INBX
122
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.27M 0.02%
48,800
+19,100
+64% +$446K
AKRO
123
DELISTED
Akero Therapeutics
AKRO
$1.27M 0.02%
27,100
+1,000
+4% +$45.8K
ETNB
124
DELISTED
89bio
ETNB
$1.24M 0.02%
65,200
-1,800
-3% -$31.6K
CYTK icon
125
Cytokinetics
CYTK
$10.9B
$1.21M 0.02%
37,100
-17,100
-32% -$633K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2023 Portfolio in Review

As of Q2 2023, Bellevue Group held 168 positions worth $7.01B, up 1.7% from $6.89B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group's Q2 2023 filing shows 9 new, 52 increased, 52 reduced and 12 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M. The largest sale was Sarepta Therapeutics, an estimated $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2023 buy was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M.
  • Bellevue Group added most to Evolent Health in Q2 2023, an estimated $40.7M increase.
  • Bellevue Group's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $57.6M.
  • Bellevue Group fully exited Pfizer in Q2 2023, selling an estimated $30.2M.
  • Bellevue Group's ten largest holdings make up 37% of its $7.01B portfolio in Q2 2023.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2023.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $7.01B.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.